Alere Inc. has made available the Alere Determine HIV-1/2 Ag/Ab Combo test, the first rapid point-of-care test that detects both HIV-1/2 antibodies and the HIV-1 p24 antigen, which can appear days after infection and prior to HIV-1/2 antibodies.
The Alere Determine HIV-1/2 Ag/Ab Combo test is a CLIA (Clinical Laboratory Improvement Amendments) moderately complex medical device that simultaneously detects free HIV-1 p24 antigen as well as both HIV-1 and HIV-2 antibodies in human serum, plasma, and venous or fingerstick whole blood specimens.
The test is currently undergoing CLIA-waiver studies to demonstrate its ease of use, safety and accuracy.
Alere Determine HIV-1/2 Ag/Ab Combo test is currently available to all health facilities and laboratories that are licensed to conduct tests of moderate complexity under the CLIA program.
For more information visit AlereHIV.com.